All data is presented in the supporting information of the manuscript.

Introduction {#sec001}
============

Chagas disease (CD), also known as human American trypanosomiasis, is a condition resulting from infection by the parasite*T*. *cruzi*. Chagas disease remains a major public health problem; between five and 18 million people are currently infected and the disease is estimated to cause more than 10,000 deaths annually\[[@pntd.0008529.ref001]\]. Globally, the annual burden is \$627.5 million in health-care costs\[[@pntd.0008529.ref002]\], and 232,000 to 806,170 disability‐adjusted life years (DALYs)\[[@pntd.0008529.ref003]\]. The Latin American region bears most of the burden of Chagas disease, accounting for at least 206,000\[[@pntd.0008529.ref002]\] to 662,000 DALYs lost\[[@pntd.0008529.ref004]\]. A study investigating the economic value of a therapeutic Chagas vaccine found that when administering standard of care benznidazole (BZN) to 1000 indeterminate patients, 148 discontinued treatment and 219 progressed to chronic disease, resulting in 119 Chagas-related deaths and 2293 DALYs, costing \$18.9 million in lifetime societal costs\[[@pntd.0008529.ref005]\]. Population migration dynamics combined with the increased risk of mothers infecting their unborn children and the increased risk of infection from blood or solid‐organ donations, means that CD has become a global problem\[[@pntd.0008529.ref006]\]. The number of infected individuals has been estimated at 300,000 in the USA,\[[@pntd.0008529.ref007]\] and 80,000 in Europe\[[@pntd.0008529.ref008]\]. Primary acute *T*. *cruzi* infection is seldom clinically evident, given its lack of defining features. CD is often asymptomatic or resembles a common viral illness, although more serious outcomes such as myocarditis or meningoencephalitis are possible. During this period, *T*. *cruzi* trypomastigotes are directly observable in the bloodstream. After this comes an indeterminate chronic phase, during which *T*. *cruzi* lodges in organ tissue in amastigote form, inducing a specific immune response. While most remain asymptomatic, 30--40% of patients progress to an advanced disease stage, usually years to decades after the initial infection. The advanced chronic phase frequently involves damage to the conduction system of the heart and the myocardium, which can result in heart failure and sudden death. In the Americas, myocarditis secondary to CD is the most common form of nonischemic cardiomyopathy\[[@pntd.0008529.ref009]\]. In other cases, CD produces gastrointestinal disorders (especially megaesophagus and megacolon), or disorders of the central or peripheral nervous system, particularly in immunocompromised patients. Serology is used to confirm a diagnosis of chronic *T*. *cruzi* infection and polymerase chain reaction (PCR) contributes to that diagnosis. For years, host‐based control was considered a difficult goal to achieve and consequently, in the 1990s, public health authority efforts were focused on primary prevention, *Triatoma infestans*‐based control, and control of blood donors to prevent infection of individuals at risk\[[@pntd.0008529.ref010]\]. In recent years, significant progress has been made in the fight against triatomines, which, added to the controls implemented by blood banks, has drastically reduced *T*. *cruzi* infections by vectors and transfusions. Interest in host‐based control, that is treating chronically infected individuals with trypanocidal therapy, has increased\[[@pntd.0008529.ref011], [@pntd.0008529.ref012]\]. Additionally, the focus on vector‐based control has left the already infected population without interventions that are potentially preventive of CCC\[[@pntd.0008529.ref013]\]. Two nitroimidazolic derivatives, BZN and nifurtimox, are the only approved trypanocidal options currently used, with no important differences in their relative efficacy, adverse effects (AEs) and cost\[[@pntd.0008529.ref014]\]. The usual recommended dose of BZN is 5 to 7 mg/kg/day orally (5--10 mg/kg for children up to 12 years old) divided into two or three times daily, for 60 days for adults. The most frequently reported side effects are skin reactions and neuropathy, which commonly result in interruption of treatment\[[@pntd.0008529.ref015]\].

Recently, several studies\[[@pntd.0008529.ref016]--[@pntd.0008529.ref018]\] suggested that the use of a simpler fixed dose of BZN may be equivalent to an adjusted dose in terms of effectiveness, simplifying its administration and enhancing compliance. In order to compare the efficacy and safety of both schemes for *T*. *cruzi* seropositive adults without CCC, we have systematically searched and extracted data from eligible studies comparing relevant clinical, parasitological, and biochemical outcomes for seropositive adults exposed to fixed and/or adjusted doses of BZN.

Methods {#sec002}
=======

We conducted a systematic review and meta-analysis following Cochrane methods,\[[@pntd.0008529.ref019]\] and the PRISMA statement for reporting\[[@pntd.0008529.ref020], [@pntd.0008529.ref021]\]. The study protocol was registered in PROSPERO (CRD42019120905).

Eligibility criteria {#sec003}
--------------------

Randomized controlled trials (RCTs) allocating adults with asymptomatic chronic Chagas disease to fixed and/or adjusted doses BZN vs placebo or other trypanocidal treatments were included. RCTs had to include people with chronic *T*. *cruzi* infection, diagnosed with positive serology by at least two of the following techniques: ELISA, indirect hemagglutination (IHA), or indirect immunofluorescence (IIF), mainly without clinically evident (i.e. symptomatic) CCC. Important safety and efficacy outcomes, including proxies as positive serology or PCR, any adverse events (AEs) and serious adverse events (SAEs) and critical patient (clinical) related outcomes, such as all-cause mortality or significant progression of CCC, were analyzed.

Search strategy {#sec004}
---------------

We searched during December 2019 the following databases: Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), MEDLINE, EMBASE, LILACS, Clinicaltrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).

The basic search strategy included the following terms: (Chagas Disease \[Mesh\] OR Chagas\[tiab\] OR Trypanosom\*\[tiab\] OR Cruzi\[tiab\] OR T.Cruzi\[tiab\]) AND (Benznidazole\[Supplementary Concept\] OR benznidazol\*\[tiab\] OR Radanil\[tiab\] OR Rochagan\[tiab\] OR N-bencil-2-acetamide\[tiab\]).

The search strategy was adapted to each database (See [S1 Text](#pntd.0008529.s001){ref-type="supplementary-material"}).

No language limitations or publication date restrictions were applied. For studies with multiple publications, we decided how to best use the data on a case-by-case basis through discussion with the principal investigators.

Additional searches included a Google search (the first 100 hits, in order of relevance, when typing Chagas benznidazol), handsearching of reference lists of systematic reviews and eligible studies retrieved with the electronic search, and verbal feedback from experts in the field.

Screening and data extraction {#sec005}
-----------------------------

Selection, data extraction, and risk of bias assessment were performed independently by pairs of reviewers from the research team. Discrepancies were solved by consensus within the team. All the study selection phases were completed using COVIDENCE, a web-based platform designed for the systematic review process. Authors of articles were contacted when necessary to obtain missing or supplementary information.

A pre-designed general data extraction form was used after pilot testing.

We extracted the source of study report, study location and setting, population, disease definition of chronic *T*. *cruzi* infection, diagnostic tests used (number and type of laboratory tests used), quality control measures, BZN and other treatment schedules, and follow-up measures.

Risk of bias (quality) assessment {#sec006}
---------------------------------

Pairs of independent reviewers assessed the risk of bias (quality) using the Cochrane Collaboration tool\[[@pntd.0008529.ref022]\]. See details in [S2 Text](#pntd.0008529.s002){ref-type="supplementary-material"}. Discrepancies were solved by consensus within the team.

Data synthesis {#sec007}
--------------

We conducted a traditional aggregate meta-analysis by using the Review Manager 5.3 software package\[[@pntd.0008529.ref023]\]. Pooled effect estimates and their 95% confidence intervals (CI), when appropriate, were generated using a random‐effects model. We reported risk ratios (RR) for dichotomous outcomes (e.g. positive serology after treatment), the Peto odds ratio (OR) for very infrequent outcomes, and the mean difference (MD) for continuous data such as antibody titers. For dichotomous data, we used the Mantel-Haenszel method, and for continuous data, we used the inverse variance method.

We described statistical heterogeneity of intervention effects by calculating the I^2^ statistic and we interpreted 0--30% as not important, 30--60% as moderate heterogeneity, and more than 60% as substantial heterogeneity. Since we assume that clinical heterogeneity is very likely to impact our review results, given the nature of the interventions included, we primarily reported the random-effects model results, however, we also applied the fixed effect model as a sensitivity analysis. We calculated all overall effects using inverse variance methods.

Where necessary, we contacted the corresponding authors of included studies up to three times to supply any unreported data.

We planned subgroup analyses (see protocol) by age of participants at time of treatment (young adults vs. older population), type of serological test (conventional serology vs. non-conventional serology), time of treatment and testing (less than ten years vs. equal or more than ten years), and region where the patient was infected (Central vs. South America). We expected, *ex ante*, to find an earlier and higher rate of seroconversion in Central America due to the presence of different parasite lineages, i.e., *T*. *cruzi* type I predominating in Central America and *T*. *cruzi* type Non-I (II, V and VI) in South America.

We planned to undertake sensitivity analyses to determine the effect of restricting the analysis to only: (a) studies with low risk of selection bias (associated with sequence generation or allocation concealment), (b) studies with low risk of performance bias (associated with issues of blinding), and (c) studies with low risk of attrition bias (associated with completeness of data).

Finally, we used the GRADE profiler software package\[[@pntd.0008529.ref024]--[@pntd.0008529.ref026]\] in order to assign a level of evidence around the data extracted and to generate pooled estimates and their CIs, and to produce summary of findings tables.

Results {#sec008}
=======

We identified 803 records through the database search and one additional record by contacting authors. After removing duplicates, 655 records were screened by title and abstract and 22 by full-text. Ultimately, 10 studies (four of them ongoing studies) met our inclusion criteria ([Fig 1](#pntd.0008529.g001){ref-type="fig"}).

![Study flow diagram.\
**O**: Objective outcomes; **S**: Subjective outcomes.](pntd.0008529.g001){#pntd.0008529.g001}

Included and ongoing studies {#sec009}
----------------------------

We included six completed RCTs\[[@pntd.0008529.ref016], [@pntd.0008529.ref017], [@pntd.0008529.ref027]--[@pntd.0008529.ref030]\] and identified four ongoing studies\[[@pntd.0008529.ref018], [@pntd.0008529.ref031]--[@pntd.0008529.ref033]\] that met our inclusion criteria(See [Table 1](#pntd.0008529.t001){ref-type="table"} and [S3 Text](#pntd.0008529.s003){ref-type="supplementary-material"}). These studies directly compared fixed vs adjusted doses of BZN. Of the included studies, four were already published\[[@pntd.0008529.ref017], [@pntd.0008529.ref028]--[@pntd.0008529.ref030]\] and details of the remaining two\[[@pntd.0008529.ref016], [@pntd.0008529.ref027]\] were obtained by personal communication with the authors.

10.1371/journal.pntd.0008529.t001

###### Main characteristics of included and ongoing studies.

![](pntd.0008529.t001){#pntd.0008529.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Short title                                                                              PI                    Start/end years   N     Countries                                    Study status   Benznidazole dose   Comparison                 Outcomes
  ---------------------------------------------------------------------------------------- --------------------- ----------------- ----- -------------------------------------------- -------------- ------------------- -------------------------- ---------------------------------------
  Rodrigues C. 1997\[[@pntd.0008529.ref028]\]                                              Rodrigues Coura, J.   \<1997            77    Brazil                                       Completed      Adjusted            Nifurtimox/ Placebo        Serology / Xenodiagnoses

  E1224\[[@pntd.0008529.ref030]\]                                                          Torrico, F.           2011/2            231   Bolivia                                      Completed      Adjusted            E1224 / Placebo            PCR

  CHAGASAZOL \[[@pntd.0008529.ref029]\]                                                    Molina, C.            2010/1            79    Spain                                        Completed      Fixed               Posaconazole               PCR

  STOP-CHAGAS\[[@pntd.0008529.ref017]\]                                                    Morillo, I.           2011/3            120   Argentina, Chile, México, Guatemala, Spain   Completed      Fixed               Posaconazole / Placebo     PCR

  BENDITA\[[@pntd.0008529.ref016]\]                                                        Torrico, F.           2017/8            210   Bolivia                                      Completed\     Fixed               E1224 / Placebo            PCR
                                                                                                                                                                                      Unpublished                                                   

  TRAENA\[[@pntd.0008529.ref027]\]                                                         Riarte, A.            1999/\            910   Argentina                                    Completed\     Adjusted            Placebo                    PCR\
                                                                                                                 2015                                                                 Unpublished                                                   Serology\
                                                                                                                                                                                                                                                    Cardiovascular Mortality, Progression

  BETTY\[[@pntd.0008529.ref032]\]                                                          Buekens, P.           2019/             600   Argentina                                    Ongoing        Fixed               Benznidazole 300 mg        PCR

  CHICAMOCHA 3\[[@pntd.0008529.ref031], [@pntd.0008529.ref047], [@pntd.0008529.ref048]\]   Villar, JC.           2015/             500   Colombia                                     Ongoing        Adjusted            Nifurtimox/ Placebo        PCR

  MULTIBENZ \[[@pntd.0008529.ref018]\]                                                     Molina, I.            2017/             240   Spain, Brazil Argentina, Colombia            Ongoing        Fixed               Benznidazole 150/400 mg    PCR

  TESEO\[[@pntd.0008529.ref033]\]                                                          Almeida, IC.          2019              450   Bolivia                                      Ongoing        Fixed               Benznidazole 150/300 mg\   RT-PCR
                                                                                                                                                                                                                         Nifurtimox 240/480 mg      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients were recruited from Argentina, Bolivia, and Spain (two studies each), and from Brazil, Chile, Mexico, and Guatemala (one study each). Three studies used an adjusted dose\[[@pntd.0008529.ref027], [@pntd.0008529.ref028], [@pntd.0008529.ref030]\] and three fixed doses\[[@pntd.0008529.ref016], [@pntd.0008529.ref017], [@pntd.0008529.ref029]\]. One study was started before 1997 and used serology and xenodiagnosis\[[@pntd.0008529.ref028]\], those that recruited patients from 1999 to 2018 used PCR for parasitological outcomes. Only one study provided long-term clinical outcomes, including cardiovascular mortality and progression of cardiomyopathy, but for comparison reasons we used a shorter follow-up period as in the majority of studies for non-clinical outcomes\[[@pntd.0008529.ref027]\]. The mean sample size was 330 (minimum 77, maximum 910).

Although the ongoing studies are not included in the evidence synthesis, we have described them in detail (see [Table 1](#pntd.0008529.t001){ref-type="table"}) in order to explain how they might be able to answer our main question in the near future. Patients in these studies are being recruited from Argentina, Bolivia, Brazil, Colombia, and Spain. Only one of them will use an adjusted dose\[[@pntd.0008529.ref031]\] and all of them will use PCR to detect presence of parasites.

Excluded studies {#sec010}
----------------

We excluded 12 studies, three of these were duplicate records. The reasons for excluding the other nine\[[@pntd.0008529.ref034]--[@pntd.0008529.ref042]\] are described in [S3 Text](#pntd.0008529.s003){ref-type="supplementary-material"}; seven of these were excluded due to a wrong study design.

Risk of bias in included studies {#sec011}
--------------------------------

Only one study was considered of unclear risk of bias for the randomization domains\[[@pntd.0008529.ref017]\]; two studies were considered of high risk for blinding assessment\[[@pntd.0008529.ref017], [@pntd.0008529.ref029]\] and one study for blinding of participants and personnel\[[@pntd.0008529.ref029]\]; and two studies presented unclear risk for selective reporting\[[@pntd.0008529.ref028], [@pntd.0008529.ref043]\](see [Fig 2](#pntd.0008529.g002){ref-type="fig"}, and in [S4 Text](#pntd.0008529.s004){ref-type="supplementary-material"}).

![Risk of bias item for each included study.\
**A**) Random sequence generation (selection bias), (**B**) allocation concealment (selection bias), (**C**) blinding of participants and personnel (performance bias), (**D**) blinding of outcome assessment (detection bias), (**E**) incomplete outcome data (attrition bias), (**F**) selective reporting (reporting bias), (**G**) other bias O: Objective outcomes, S: subjective outcomes.](pntd.0008529.g002){#pntd.0008529.g002}

Effects of interventions {#sec012}
------------------------

In considering the main question of this review, we focused the results on comparisons that included both fixed and adjusted doses of BZN, for which we presented GRADE summary of finding tables.

Benznidazole fixed vs adjusted dose {#sec013}
-----------------------------------

There was no head-to-head study exploring this comparison but, based on inferences from indirect comparisons of BZN-treated patients versus placebo, using PCR at one year and safety outcomes (see BZN versus placebo below), we did not observe important differences between fixed and adjusted doses (see [Table 2](#pntd.0008529.t002){ref-type="table"}). The certainty of evidence for these outcomes was downgraded one or two levels because of indirectness.

10.1371/journal.pntd.0008529.t002

###### Summary of findings: Benznidazole fixed vs adjusted dose.

![](pntd.0008529.t002){#pntd.0008529.t002g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                             Impact                                                                                                                       № of participants\                            Certainty of the evidence
                                                                                                                                                                   (studies)                                     
  ----------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ---------------------------------------------
  **Efficacy\***                                                                                                                                                                                                 

  **Positive PCR**                    No important difference between fixed and adjusted dose (subgroup differences I^2^ = 0%)                                     152\                                          ⨁⨁⨁◯[^1^](#t002fn002){ref-type="table-fn"}\
                                                                                                                                                                   (2 RCTs)                                      MODERATE

  **Cardiovascular mortality**        Based only in the surrogate outcome + PCR, differences between groups on critical outcomes are uncertain                     152\                                          ⨁◯◯◯[^2^](#t002fn003){ref-type="table-fn"}\
                                                                                                                                                                   (2 RCTs)                                      VERY LOW

  **Progression of cardiomyopathy**   152\                                                                                                                         ⨁◯◯◯[^2^](#t002fn003){ref-type="table-fn"}\   
                                      (2 RCTs)                                                                                                                     VERY LOW                                      

  **Safety**^**\#**^                                                                                                                                                                                             

  **Drug discontinuation**            No important difference between fixed and adjusted dose (Subgroup differences: I^2^ = 0%)                                    846\                                          ⨁⨁⨁◯[^1^](#t002fn002){ref-type="table-fn"}\
                                                                                                                                                                   (3 RCTs)                                      MODERATE

  **Peripheral neuropathy**           769\                                                                                                                         ⨁⨁⨁◯[^1^](#t002fn002){ref-type="table-fn"}\   
                                      (2 studies)                                                                                                                  MODERATE                                      

  **Mild rash**                       769\                                                                                                                         ⨁⨁⨁◯[^1^](#t002fn002){ref-type="table-fn"}\   
                                      (2 studies)                                                                                                                  MODERATE                                      

  **Any serious adverse events**      Based only in the surrogate outcome drug discontinuation, differences between groups on this critical outcome is uncertain   846\                                          ⨁⨁◯◯[^3^](#t002fn004){ref-type="table-fn"}\
                                                                                                                                                                   (3 RCTs)                                      LOW
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Refer to text for benznidazole versus placebo: Efficacy (PCR at one year\*) and Safety^\#^

^1^Downgraded one level due to serious indirectness, since these are inferences from subgroup analysis of comparisons between BZN and placebo.

^2^Downgraded two levels due to due to very serious indirectness (important uncertainty between the surrogate outcome + PCR and the critical outcomes cardiovascular mortality and progression of cardiomyopathy) and methodological limitations to answering this question.

^3^Downgraded one level due to serious indirectness, since there is uncertainty between surrogate outcome drug discontinuation and SAEs.

Benznidazole at different fixed doses {#sec014}
-------------------------------------

We identified the unpublished study BENDITA\[[@pntd.0008529.ref016]\], which did not find important differences in positive PCR between BZN 150 vs 300 for 8 weeks (RR 1.00; IC95% 0.24--4.18), 150 vs 300 for 4 weeks (RR 1.20; IC95% 0.27--5.25), and 150 vs 300 for 2 weeks (RR 0.86; IC95% 0.21, 3.47). The authors also found no differences in AEs for the same comparisons: RR 0.88 (IC95% 0.56, 1.36), RR 1.05 (IC95% 0.65, 1.69), and RR 0.86 (IC 95% 0.49, 1.50) respectively. There were very few serious adverse events (SAEs) and drug discontinuations due to AEs, and no evidence of differences between groups. However, the study design was unpowered to detect differences between arms.

Benznidazole versus placebo {#sec015}
---------------------------

Efficacy was determined by positive serology, positive PCR, positive xenodiagnosis, mean reduction of antibody titer, mean reduction in PCR load, and clinical outcomes at the end of follow-up.

Positive serology: we identified one published study\[[@pntd.0008529.ref028]\] without differences between groups (RR 1.00; IC95% 0.93--1.08) and one study\[[@pntd.0008529.ref027]\] that favors treatment with BZN (RR 0.88; IC95% 0.84--0.93), both using an adjusted dose. The pooled RR was 0.94 (IC95% 0.82--1.08) and the certainty of evidence was considered low (see [Fig 3](#pntd.0008529.g003){ref-type="fig"}). The TRAENA study\[[@pntd.0008529.ref027]\] showed a RR of 0.65 (IC95% 0.58--0.63) at six years.

![Positive serology at one year.\
**A**) Random sequence generation (selection bias), (**B**) allocation concealment (selection bias), (**C**) blinding of participants and personnel (performance bias), (**D**) blinding of outcome assessment (detection bias), (**E**) incomplete outcome data (attrition bias), (**F**) selective reporting (reporting bias), (**G**) other bias.](pntd.0008529.g003){#pntd.0008529.g003}

Positive PCR: both the fixed\[[@pntd.0008529.ref017]\] and adjusted doses\[[@pntd.0008529.ref016], [@pntd.0008529.ref030]\] of BZN were effective at reducing positive PCR at one year against placebo (RR 0.20; IC95% 0.10--0.30) without differences in subgroups between the fixed dose of 300 mg/day for 14 to 56 days and the adjusted dose: RR 0.12 (IC95% 0.04--0.36) and RR 0.19 (IC95% 0.10--0.37), respectively. The significance of the test for subgroup differences was Chi^2^ = 0.56, df = 1 (P = 0.45), I^2^ = 0% (see [Fig 4](#pntd.0008529.g004){ref-type="fig"} and [Table 3](#pntd.0008529.t003){ref-type="table"}).

10.1371/journal.pntd.0008529.t003

###### Summary of findings: Benznidazole versus placebo.

![](pntd.0008529.t003){#pntd.0008529.t003g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                      Absolute effects (95% CI)   Relative effect (95% CI)   № of participants\    Certainty of the evidence   
                                                                                                      (studies)                                         
  -------------------------------------------- --------------------------- -------------------------- --------------------- --------------------------- -------
  **Positive PCR**                             883 per 1.000               **150 per 1.000**\         **RR 0.20**\          152\                        ⨁⨁⨁⨁\
                                                                           **(88 to 265)**            **(0.16 to 0.25)**    (2 RCTs)                    HIGH

  \- Fixed dose 300 mg/day for 14 to 56 days   833 per 1.000               **100 per 1.000**\         **RR 0.12**\          60\                         ⨁⨁⨁⨁\
                                                                           **(33 to 300)**            **(0.04 to 0.36)**    (1 RCT)                     HIGH

  \- Adjusted dose                             915 per 1.000               **174 per 1.000**\         **RR 0.19**\          92\                         ⨁⨁⨁⨁\
                                                                           **(91 to 339)**            **(0.10 to 0.37)**    (1 RCT)                     HIGH

  **Drug discontinuation**                     24 per 1.000                **181 per 1.000**\         **RR 7.42**\          846\                        ⨁⨁⨁⨁\
                                                                           **(61 to 533)**            **(2.51 to 21.91)**   (3 RCTs)                    HIGH

  \- Fixed dose                                33 per 1.000                **333 per 1.000**\         **RR 10.00**\         60\                         ⨁⨁⨁⨁\
                                                                           **(45 to 1.000)**          **(1.36 to 73.33)**   (1 RCT)                     HIGH

  \- Adjusted dose                             24 per 1.000                **150 per 1.000**\         **RR 6.35**\          786\                        ⨁⨁⨁⨁\
                                                                           **(30 to 753)**            **(1.27 to 31.86)**   (2 RCTs)                    HIGH

  **Peripheral neuropathy**                    2 per 1000                  **10 per 1000**\           **RR 4.27**\          919\                        ⨁⨁⨁⨁\
                                                                           **(2 to 47)**              **(0.94 to 19.40)**   (3 RCTs)                    HIGH

  \- Fixed dose                                0 per 1000                  **0 per 1000**\            **RR 1.52**\          210\                        ⨁⨁⨁⨁\
                                                                           **(0 to 0)**               **(0.16 to 14.32)**   (2 RCTs)                    HIGH

  \- Adjusted dose                             3 per 1000                  **28 per 1000**\           **RR 10.14**\         709\                        ⨁⨁⨁⨁\
                                                                           **(4 to 221)**             **(1.31 to 78.81)**   (1 RCT)                     HIGH

  **Mild rash**                                67 per 1000                 **357 per 1000**\          **RR 5.32**\          919\                        ⨁⨁⨁⨁\
                                                                           **(246 to 520)**           **(3.66 to 7.74)**    (3 RCTs)                    HIGH

  \- Fixed dose                                50 per 1000                 **312 per 1000**\          **RR 6.24**\          210\                        ⨁⨁⨁⨁\
                                                                           **(111 to 876)**           **(2.22 to 17.52)**   (2 RCTs)                    HIGH

  \- Adjusted dose                             70 per 1000                 **363 per 1000**\          **RR 5.19**\          709\                        ⨁⨁⨁⨁\
                                                                           **(243 to 544)**           **(3.47 to 7.77)**    (1 RCT)                     HIGH
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

![Positive PCR at one year.\
**A**) Random sequence generation (selection bias), (**B**) allocation concealment (selection bias), (**C**) blinding of participants and personnel (performance bias), (**D**) blinding of outcome assessment (detection bias), (**E**) incomplete outcome data (attrition bias), (**F**) selective reporting (reporting bias), (**G**) other bias.](pntd.0008529.g004){#pntd.0008529.g004}

Positive xenodiagnosis: only one study provided data about an adjusted dose\[[@pntd.0008529.ref028]\], favoring BZN (RR 0.12, 95% CI 0.04 to 0.36; participants = 60; studies = 1).

Mean reduction in PCR load (GMT one year): Two studies provided data about an adjusted dose\[[@pntd.0008529.ref027], [@pntd.0008529.ref030]\] and showed no significant difference: (MD -0.48; 95% CI -1.19, 0.23, participants = 480; studies = 2).

Mean reduction of antibody titer at one year: only one study (92 participants) provided data about an adjusted dose\[[@pntd.0008529.ref030]\] and showed no difference with placebo (Conventional ELISA: MD 0.01, 95% CI -0.17 to 0.19 and AT CL−ELISA: MD 0.01, 95% CI -0.07 to 0.09) except when using the geometric mean measured by AT CL−ELISA (MD -0.57, 95% CI -1.08 to -0.06).

Clinical outcomes at the end of follow-up: one long-term study (n = 713) that used an adjusted dose of BZN vs. placebo provided data about these outcomes,\[[@pntd.0008529.ref027]\] and showed a RR of 0.89 (95% CI 0.62 to 1.26) for progression of cardiomyopathy, RR 1.18, (95% CI 0.40 to 3.49) for cardiovascular mortality and RR 0.38 (95% CI 0.10 to 1.42) for pacemaker implantation, implantable cardioverters or severe arrhythmia with hemodynamic unbalance, and cardiac failure.

As expected, the frequency of AEs is higher with BZN (see Supporting Information. RevMan, and Raw and analysis data). Only three outcomes presented studies that used fixed or adjusted dose against placebo: drug discontinuation, peripheral neuropathy (considered SAEs), and mild rash (considered non-serious AEs).

Drug discontinuation: both the fixed and adjusted doses showed more drug discontinuation than placebo and we found no subgroup difference: Test for subgroup differences: Chi^2^ = 0.12, df = 1 (P = 0.73), I^2^ = 0% 9 (see [Fig 5](#pntd.0008529.g005){ref-type="fig"} and [Table 3](#pntd.0008529.t003){ref-type="table"}).

![Drug discontinuation.\
**A**) Random sequence generation (selection bias), (**B**) allocation concealment (selection bias), (**C**) blinding of participants and personnel (performance bias), (**D**) blinding of outcome assessment (detection bias), (**E**) incomplete outcome data (attrition bias), (**F**) selective reporting (reporting bias), (**G**) other bias.](pntd.0008529.g005){#pntd.0008529.g005}

Peripheral neuropathy: we found no subgroup differences: Test for subgroup differences: Chi^2^ = 1.50, df = 1 (P = 0.22), I^2^ = 33.2%. See [Fig 6](#pntd.0008529.g006){ref-type="fig"} and [Table 3](#pntd.0008529.t003){ref-type="table"}.

![Peripheral neuropathy.\
**A**) Random sequence generation (selection bias), (**B**) allocation concealment (selection bias), (**C**) blinding of participants and personnel (performance bias), (**D**) blinding of outcome assessment (detection bias), (**E**) incomplete outcome data (attrition bias), (**F**) selective reporting (reporting bias), (**G**) other bias.](pntd.0008529.g006){#pntd.0008529.g006}

Mild rash: we found no subgroup difference: Test for subgroup differences: Chi^2^ = 0.14, df = 1 (P = 0.93), I^2^ = 0%) (see [Fig 7](#pntd.0008529.g007){ref-type="fig"} and [Table 3](#pntd.0008529.t003){ref-type="table"}).

![Mild rash.\
(**1**) Bendita 20117 (Maculo-papular rash + papular rash + erythema. **A**) Random sequence generation (selection bias), (**B**) allocation concealment (selection bias), (**C**) blinding of participants and personnel (performance bias), (**D**) blinding of outcome assessment (detection bias), (**E**) incomplete outcome data (attrition bias), (**F**) selective reporting (reporting bias), (**G**) other bias.](pntd.0008529.g007){#pntd.0008529.g007}

Benznidazole versus posaconazole {#sec016}
--------------------------------

We identified two studies that used fixed-dose BZN versus posaconazole\[[@pntd.0008529.ref017], [@pntd.0008529.ref029]\] and considering the longest follow-up period, both favored BZN (RR 0.24, 95% CI 0.06 to 0.93; participants = 112; studies = 2; I^2^ = 81%). Test for subgroup differences by follow-up: Chi^2^ = 4.17, df = 1 (P = 0.04), I^2^ = 76.0% due to higher effect in Morillo 2017 (follow-up 360 days)\[[@pntd.0008529.ref017]\] than in Molina 2014 (follow-up 280 days)\[[@pntd.0008529.ref029]\].

Subgroup analysis and sensitivity analysis {#sec017}
------------------------------------------

Due to the low number of included studies it was not possible to conduct the planned subgroup analyses, except for the fixed and adjusted doses related to the question of our review.

For the same reason, it was not possible to conduct the planned sensitivity analyses, restricting the analysis to only studies with low risk of selection bias (associated with sequence generation or allocation concealment). Morillo et al.\[[@pntd.0008529.ref017]\] (unclear risk of bias for this domain) was the only fixed-dose study included in the subgroup comparison between fixed and adjusted doses of BZN.

All studies included in the subgroup comparison between fixed and adjusted doses of BZN were of low risk of performance bias (associated with issues of blinding) and low risk of attrition bias (associated with completeness of data) except for TRAENA\[[@pntd.0008529.ref027]\]. We found consistency of results applying both fixed-effect and random-effects models and also using OR and RD.

Discussion {#sec018}
==========

The only drugs with proven efficacy against Chagas disease are BZN and nifurtimox. BZN is used in children and adults and is registered for use in adjusted-dose schemes. However, some investigators have proposed the more flexible use of fixed dosing regardless of body weight. After searching all completed and ongoing RCTs involving BZN at any dose, we found no direct comparison between fixed and adjusted doses of BZN.

We only found one efficacy outcome (positive PCR) and three safety outcomes (drug discontinuation, peripheral neuropathy, and mild rash) that allowed the subgroup comparisons between fixed and adjusted doses of BZN \[[@pntd.0008529.ref016], [@pntd.0008529.ref017], [@pntd.0008529.ref027], [@pntd.0008529.ref028], [@pntd.0008529.ref030]\] The low or null I^2^ for all these subgroup comparisons suggest no important clinical, methodological, or statistical differences in the observed effects by type of dosing. Since these are inferences from indirect comparisons of BZN-treated patients versus placebo, the certainty of evidence for these outcomes was consequently downgraded one or two levels because of indirectness.

We found a high certainty of evidence for the direct comparisons between BZN versus placebo for the efficacy outcome (positive PCR) and for the three safety outcomes (drug discontinuation, peripheral neuropathy and mild rash). However, these four outcomes are considered as moderate certainty of the evidence for the comparison fixed vs adjusted dose of benznidazole after downgrading one level due to indirectness (indirect comparisons). The certainty of the evidence was considered to be very low for cardiovascular mortality and progression of cardiomyopathy due to significant uncertainty between the surrogate positive PCR outcome and these critical outcomes. The certainty of the evidence was considered low for any SAE due to uncertainty between this outcome and the surrogate outcome drug discontinuation. See [Table 2](#pntd.0008529.t002){ref-type="table"} (based on indirect comparisons) and [Table 3](#pntd.0008529.t003){ref-type="table"} (for direct comparisons between BZN and placebo by type of dose).

We found six related systematic reviews that showed similar results in terms of the effect of interventions against placebo, however, none of them addressed our question concerning the comparison of fixed and adjusted doses of BZN \[[@pntd.0008529.ref038], [@pntd.0008529.ref039], [@pntd.0008529.ref042], [@pntd.0008529.ref044]--[@pntd.0008529.ref046]\]. Observational studies suggest that treatment could be better that no treatment even in the early phases of CCC\[[@pntd.0008529.ref046]\]. Unfortunately, non-RCT studies used adjusted doses of BZN, not allowing the assessment of subgroup analysis by BZN scheme. Unlike other reviews, we only included RCTs to reduce the risk of bias, but, as was the case for the previous studies, we had to deal with differences in the populations studied, follow-up periods, diagnostic techniques, and sample size.

Demonstration that a fixed dose of BZN has a similar profile in relation to safety and efficacy would allow a review of the current guidelines and the recommendation of fixed doses, eliminating one barrier to treatment management, and improving compliance by patients and health workers.

The strengths of this systematic review of RCTs include the registration of its protocol, the complete literature search, the rigorous Cochrane methods used, the participation of most principal investigators of the RCTs included, and the inclusion of valuable unpublished data. All these factors make our study the most complete evidence synthesis currently available that addresses the comparative efficacy and safety of adjusted-dose BZN for *T*. *cruzi* seropositive adults mainly without CCC.

The population included in the trials is representative of the population of adults with chronic Chagas disease without cardiomyopathy, however important limitations need to be mentioned. First of all, the absence of direct comparisons between fixed and adjusted doses of BNZ, and the assessments of critical outcomes should be noticed. Additionally, the paucity of studies prevented us from performing our planned subgroup and sensitivity analyses. The unpublished TRAENA study\[[@pntd.0008529.ref027]\] was the only one that succeeded in assessing long-term clinical outcomes.

Individual patient data (IPD) meta-analysis could address these issues, for example by including cumulative dose assessments. Moreover, network IPD meta-analysis could formally enhance indirect comparisons.

Conclusion {#sec019}
----------

Based on a low to very low certainty of evidence for critical clinical outcomes and a moderate certainty of evidence for important outcomes, fixed and adjusted doses of BZN might be considered equivalent in terms of efficacy and safety.

An IPD meta-analysis would allow us to conduct the planned subgroup analysis and meta-regressions, but given the absence of a direct comparison between fixed and adjusted doses of BZN, the only approach to gain in certainty of evidence to address the objective of the review would be an IPD network-meta-analysis---an approach which our research group is currently following.

Supporting information {#sec020}
======================
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Dear Dr. Ciapponi,

Thank you very much for submitting your manuscript \"Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board, which appreciated the attention to an important topic. We will likely consider your manuscript for publication, providing that you modify the manuscript according to the editorial review recommendations.

We noted several problems with manuscript formatting as detailed bellow. Please, proceed to fix the texts, formatting and graphs and return the manuscript for proper editorial flow as soon as possible.

Please prepare and submit your revised manuscript within 10 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.
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Before we send the manuscript out for peer revision, we would like to request the authors to review the text and to fix the figure 3. The text in lines 447- refers to serology outcome evaluation, but refers to figure 4, which show PCR data whereas supposedly it should refer to figure 3, which is very confusing. The title of what seems to be figure 3 is the same as figure 4, but the data apparently refers to a different data set, as it is supposed to be. However, it is not clear by looking at the figure what is the data being displayed.

In addition, we would like to request the authors to follow authors guidelines in formatting the manuscript. Although, Plos NTDs might be very flexible in a first submission regarding to formatting, there are several problems with the manuscript that makes the reading annoying:

1- References are repeated in between methods sessions and in the end of the manuscript

2- All tables are repeated in the methods session and in the end of the manuscript

3- Legend of table 2 is misplaced between the discussion session.

Please, proceed to fix the texts, formatting and graphs and return the manuscript for proper editorial flow as soon as possible.
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While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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Dear Dr. Ciapponi,

Thank you very much for submitting your manuscript \"Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

The manuscript was evaluated by three experts in field. One reviewer rejected the manuscript based on the limited number papers found to be included in the meta-analysis. The editors agree that the limited number of manuscript imposes a limitation, but we acknowledge that the authors are aware of the limitations, which are disclosed in the discussion. We are requesting the authors to perform minor revision as they find appropriate on the suggestions offered by reviewer \#3.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  
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Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.
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The manuscript was evaluated by three experts in field. One reviewer rejected the manuscript based on the limited number papers found to be included in the meta-analysis. The editors agree that the limited number of manuscript imposes a limitation, but we acknowledge that the authors are aware of the limitations, which are disclosed in the discussion. We are requesting the authors to perform minor revision as they find appropriate on the suggestions offered by reviewer \#3.
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**Methods**
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-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: While the authors present an interesting premise this study has some issues.

They propose to determine the comparative safety and efficacy of a fixed dose of benznidazole (BZN) with an adjusted dose for the treatment of T. cruzi seropositive adults without cardiomyopathy through a systematic review and a meta-analysis.

After the search they found ten studies that meet the inclusion criteria. However, four of them are ongoing and two are unpublished. So, these studies should not be included in the analysis. They did not find any study comparing a fixed dose X an adjusted dose of BZN. All these together make difficult to perform a meta-analysis study and address this important question.

So, this manuscritp should be rejected

Reviewer \#2: In my opinion, after authors revision, the study is clearly articulated with hypothesis, the design is appropriate to the stated objectives. And, despite of sample size is very low the conclusion is suitable from found results.

Reviewer \#3: The study objective was properly stated. Method and adequate analysis were done.
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**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: Figure 3 is missing

Reviewer \#2: The results are presented clearly and they are completely matched to analysis plan.

Reviewer \#3: The results met planned analysis and were presented clearly. Study importance as well as limitations were adequately described.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: Conclusions can not be supported by the meta-analysis performed. Among the ten studies selected two of them have not yet been published and four were ongoing studies and should no be included in the analysis.

Reviewer \#2: The conclusion is supported by the data presented, the limitations are presented and clearly described.

Reviewer \#3: The conclusions provided are in accord with results presented and data analysed in the study.
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**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: NO

Reviewer \#2: There is no necessity of data modification, after authors revision.

Reviewer \#3: (No Response)
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**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: (No Response)

Reviewer \#2: Despite of small number of eligible studies the paper is important because direction of specific Chagas disease treatment is not is not clear yet.

Reviewer \#3: The study evaluated and reviewed available literature to understand differential in treatment dosage for chagas disease. The result of the meta-analysis provide useful and contribute to existing knowledge about the disease and more importantly, serve as a background on which a ore significant experimental study can be conducted.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Dear Dr. Ciapponi,

We are pleased to inform you that your manuscript \'Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.
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We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.
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